Reaffirming the EPS guidance, especially when it aligns with consensus estimates, typically instills confidence in investors about the company's financial health and operational stability. The inclusion of expected disruption costs from Change Healthcare services in the guidance demonstrates transparency and may mitigate negative reactions from investors. However, the exclusion of direct response costs and the Brazil sale impact could mean that the actual financial performance might vary, but the company's confidence in meeting its targets likely outweighs these concerns in the short term.